Cardiology

Your Article Summary

See Latest Articles

Hormone therapy and risk of myocardial infarction: a national register study
European Heart Journal, 10/30/08

Løkkegaard E et al. – A national cohort study shows that hormone therapy (HT) regimen and route of application may modify the influence of HT on the risk of myocardial infarction (MI)

• Study of the risk of MI as a result of HT
• Focus on the influence of age, HT duration, various regimens and routes, progestagen type, and estrogen dose
• Review of 698,098 healthy Danish women (age 51–69 yrs) followed 1995–2001
• Daily updated national capture on HT determined based on central prescription registry

• National registers identified 4947 MI incidents
• Overall, no increased risk of MI with current HT compared with women who never used HT
• Risk increased with longer duration for younger women
• In all age groups, highest risk of MI was with continuous HT regimen
• No increased risk with unopposed estrogen, cyclic combined therapy, or tibolone
• Significantly lower risk with dermal vs oral unopposed estrogen therapy
• No associations with progestagen type or estrogen dose

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences
Vascular Health and Risk Management, 11/30/09

Vernakalant hydrochloride for the treatment of atrial fibrillation
Expert Opinion on Investigational Drugs, 11/30/09

Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/30/09

 See all of Clinical Pharmacology